Welcome & Introduction

Biomarkers in Head & Neck Cancer

Panel Discussion - Management of Locally Advanced Head & Neck Cancers

Nivolumab + ipilimumab vs EXTREME regimen as first line treatment for recurrent metastatic squamous cell carcinoma of the head and neck

A Phase II trial of Pembrolizumab and Cabozantinib in Patients with Recurent Metastatic Head and Neck Squamous Cell Carcinoma

A Phase II trial of Pembrolizumab and Cabozantinib in Patients with Recurrent Metastatic Head and Neck Squamous Cell Carcinoma

Cetuximab docetaxel & cisplatin versus platinum fluorouracil & cetuximab as first line treatment in patients with recurrent or metastatic head & neck

Salvage surgery for Recurrent SCC Head & Neck

Panel Discussion - Management of Recurrent & metastatic Head & Neck Squamous Cell Carcinoma

Proton Therapy for Oral Cavity Cancers

Inaugural Function

Treatment Intensification in Locoregionally Advanced Head & Neck Squamous Cell Carcinoma

Approach to Salivary Gland tumors Role of anti Her2 therapy

Closing Remarks

Biomarkers in Head & Neck Cancer

Panel Discussion - Management of Locally Advanced Head & Neck Cancers

Nivolumab + ipilimumab vs EXTREME regimen as first line treatment for recurrent metastatic squamous cell carcinoma of the head and neck

A Phase II trial of Pembrolizumab and Cabozantinib in Patients with Recurrent Metastatic Head and Neck Squamous Cell Carcinoma

Cetuximab docetaxel & cisplatin versus platinum fluorouracil & cetuximab as first line treatment in patients with recurrent or metastatic head & neck

Salvage surgery for Recurrent SCC Head & Neck

Panel Discussion - Management of Recurrent & metastatic Head & Neck Squamous Cell Carcinoma

Treatment Intensification in Locoregionally Advanced Head & Neck Squamous Cell Carcinoma

Approach to Salivary Gland tumors Role of anti Her2 therapy